To meet growing demands of advanced therapy manufacturing, production architectures must shift towards agile, efficient manufacturing systems. By integrating robotic gloveless isolator (RGI) technology into bioproduction, manufacturers can meet the needs of plasmid DNA, viral vector, and mRNA-based medicines while maintaining compliance with stringent regulatory standards.
Read the full article by Peter Boman (NorthX Biologics), and Zach Hartman (Cytiva), in Cell & Gene Therapy Insights here.
NorthX Biologics is a CDMO and Innovation Hub in Advanced Biologics, with +30 years of GMP production experience. The team provides process development and GMP manufacturing services with expertise in plasmid DNA, mRNA, proteins, cells and other advanced biologics. Headquartered in the heart of Sweden, the team serves customers worldwide and in 2021 was recognized as a national innovation hub for advanced therapeutics and vaccines. NorthX Biologics has the ambition to become a leading cell and gene therapy manufacturer and partner of choice for innovative drug development companies.
For more news, follow us on LinkedIn
In an increasingly unstable world, Sweden is taking decisive steps to secure access to critical pharmaceuticals during crises and war. As part of a broader government initiative, highlighted in a ...
Bacterially derived extracellular vesicles (EVs) such as Outer Membrane Vesicles (OMVs) have emerged as an attractive new modality for both immunotherapy and as vectors for nucleotides and proteins. Being a ...
Stem cells have revolutionized the field of regenerative medicine, offering promising solutions for various medical conditions, including difficult-to-heal skin wounds. This review focuses on the background and manufacturing processes of ...